Upcoming and Past Events
Amarex is pleased to announce its role as a presenting sponsor at BioTaiwan 2018, held July 18-22 at TWTC Nangang Exhibition Hall in Taipei, Taiwan. With biotechnology booming in Taiwan, and with the opening of Amarex Taiwan earlier this year, this conference offers growth opportunities for Amarex as a member of the global life sciences community.
On Wednesday, July 18 at 16:30 in Ballroom B, President & CEO of Amarex, Dr. Kazem Kazempour, will keynote on the topic of FDA Clinical and Regulatory Trends on Accelerating Approval of Biological Products. The presentation will examine the latest strategies for FDA approval, discuss the application of FDA guidelines to accelerate research development, and offer a number of enrichment strategies and adaptive trial designs that lead to successful outcomes for clinical trials.
Amarex has provided steady growth of services to Taiwanese organizations for the past ten years, and has worked to build a strong international client base for the past 15 years, notably in Asia, to help bring non-US products to the US market. Amarex has a unique understanding of the challenges related to global clinical product development.
Dr. Kazem Kazempour, President & CEO of Amarex Clinical Research, will present on the topic of US FDA Novel Regulatory Strategies for Accelerated Approval: Acceptance of Clinical Trial Data from Asia, at BIO KOREA 2018, held May 9-11 at Starfield COEX Mall in Seoul, South Korea.
Over the last 15 years, Dr. Kazempour has focused on building a strong international client base, with notable development in Asia, to help bring non-US products to the US market. The newly formed affiliate organization, Amarex Taiwan, LLC, was established to offer greater breadth and depth of services to Amarex’s Taiwanese client base. With experience working both at the FDA and with the FDA (representing Amarex’s clients), Dr. Kazempour has unparalleled expertise developing advantageous FDA approval strategies for both US and non-US clients. In this presentation, Dr. Kazempour will discuss the necessity of international collaboration, key elements that expedite FDA market approval and customized strategies for a successful FDA defense. Dr. Kazempour will present on Wednesday, May 09 at 13:00 in Room 301A.
Amarex staff members will also be present at the BIO KOREA 2018 exhibit hall booth #F47
Focusing on the most pressing challenges and opportunities to bring rare disease therapies to patients faster.
Amarex Clinical Research will exhibit at World Orphan Drug Congress USA 2018 and Dr. Kazem Kazempour, President and CEO of Amarex, will keynote on the topic of Orphan Drug Development: Using Outside Data for Marketing with the US FDA.
With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe for high-level networking, pre-scheduled partnering meetings, strategic panel discussions and more.
This event is expected to draw over 3,800 industry attendees for three days of high level networking, representing upwards of 2,000 companies from over 60 countries.
Partnering as an overall business strategy has transformed drug development in bringing together innovators and visionaries with seasoned experts from every corner of the globe.
BIO-Europe is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and financial sectors, offering networking opportunities, workshop and panel participation, a high profile exhibition, and private, prescheduled one-to-one meetings.
Amarex reports continued business growth working with Taiwan’s biotech companies. Amarex’s Taiwan office provides an excellent platform for serving Taiwan and other Asian based clients. Amarex looks forward to continuing to help Asian companies bring their products to the US market.
In mid-July Amarex was a sponsor at BioTaiwan 2018. Amarex CEO, Dr. Kazem Kazempour, gave a talk on US FDA marketing approval strategies to accelerate approval of biological products.
Amarex will participate in the 2018 Medical Device Clinical Investigation Conference, Sept 5-6 at the GIS TAIPEI TECH Convention Center. MDCIC is sponsored by the Taiwan FDA and focuses on international regulatory and clinical trial design for medical device development. Dr. Kazempour will present at the conference on Thursday, Sept 6 at 14:20. His topic is “Acceptance of Foreign Clinical Data to Support Medical Device Applications and Submissions to US FDA”.
Dr. Kazempour will also make a keynote speech at The TRANS Conference 2018 in Taipei, on Sept 8 at 10:50. This is one of the largest innovative entrepreneurship symposiums for the biomedical and healthcare fields within the Asian market. His topic is “Inside FDA’s Latest Digital Health Developments”. Embracing digital health technologies, the US FDA is making its policies and processes more efficient to encourage digital health innovation. Dr. Kazempour will examine the latest regulatory paradigm from the US FDA.
To view the agenda or to register for TRANS 2018, visit https://www.transhs.asia/. For more information on the 2018 Medical Device Clinical Investigation Conference, visit http://www.pitdc.org.tw/news_detail.php?pk=37 or register for participation in the webcast at https://goo.gl/forms/4zNcay5GjAVtUlP62.